Scarica l'app Stockscreener
8.38
4.62%
0.37
Precedente Chiudi:
$8.01
Aprire:
$7.77
Volume 24 ore:
215.11K
Relative Volume:
0.26
Capitalizzazione di mercato:
$309.22M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-3.3258
EPS:
-2.5197
Flusso di cassa netto:
-
1 W Prestazione:
-13.70%
1M Prestazione:
-16.87%
6M Prestazione:
+376.14%
1 anno Prestazione:
+280.91%
Intervallo 1D:
$7.3129
$8.38
Intervallo di 1 settimana:
$7.21
$9.98
Portata 52W:
$0.8786
$12.09
Adlai Nortye Ltd Adr Stock (ANL) Company Profile
Nome
Adlai Nortye Ltd Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare ANL vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANL
Adlai Nortye Ltd Adr
|
8.38 | 295.57M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Adlai Nortye Ltd Adr Stock (ANL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-13 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-06-02 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-09-04 | Iniziato | H.C. Wainwright | Buy |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
Adlai Nortye Ltd Adr Borsa (ANL) Ultime notizie
Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (GUTS), Ionis Pharmaceuticals (IONS) and Axsome Therapeutics (AXSM) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Palvella Therapeutics (PVLA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB), Integer Holdings (ITGR) and Tonix Pharma (TNXP) - The Globe and Mail
Has Adlai Nortye Ltd. Sponsored ADR (ANL) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Should I buy Adlai Nortye Ltd. Sponsored ADR (ANL) - Zacks Investment Research
Adlai Nortye upgraded to Buy at H.C. Wainwright as AN9025 enters clinic - TipRanks
H.C. Wainwright upgrades Adlai Nortye stock rating to Buy with $16 target - Investing.com South Africa
Adlai Nortye Doses First Patient in Global Phase 1 Trial of Pan-RAS Inhibitor AN9025 - TipRanks
Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations - GlobeNewswire Inc.
Short Interest in Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Rises By 458.7% - MarketBeat
Adlai Nortye Secures $140 Million PIPE Financing to Support Oncology Pipeline - The Globe and Mail
Adlai Nortye raises $140 million in private placement By Investing.com - Investing.com South Africa
Adlai Nortye prices 64.6M shares at $2.17 in private placement - TipRanks
Adlai Nortye raises $140 million in private placement - Investing.com
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Sees Large Decrease in Short Interest - Defense World
AIFU Inc. – Sponsored ADR (NASDAQ:AIFU) Short Interest Update - Defense World
United States shares mixed at close of trade; Dow Jones Industrial Average up 0.11% By Investing.com - Investing.com India
United States shares mixed at close of trade; Dow Jones Industrial Average up 0.11% - Investing.com India
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.11% - Investing.com
Lucid Capital Markets initiates coverage on Adlai Nortye stock with Buy rating - Investing.com India
Lucid Capital Markets initiates coverage on Adlai Nortye stock with Buy rating By Investing.com - Investing.com South Africa
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Short Interest Update - MarketBeat
What's going on in today's after hours session - ChartMill
Analysts’ Top Healthcare Picks: Kura Oncology (KURA), UnitedHealth (UNH) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Aprea Therapeutics (APRE), Arcellx Inc (ACLX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Travere Therapeutics (TVTX) and Beyond Air (XAIR) - The Globe and Mail
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Sees Significant Increase in Short Interest - Defense World
Short Interest in Global X Social Media ETF (NASDAQ:SOCL) Increases By 7,184.3% - Defense World
TerraVest Industries (TSE:TVK) Price Target Raised to C$209.00 at Canaccord Genuity Group - Defense World
Paycom Software (NYSE:PAYC) Price Target Cut to $185.00 by Analysts at Barclays - Defense World
Teledyne Technologies (NYSE:TDY) Given New $579.00 Price Target at Barclays - Defense World
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Short Interest Up 6,821.4% in December - MarketBeat
Adlai Nortye narrows first-half 2025 loss as oncology pipeline advances - MSN
Why Baidu Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket - Sahm
Adlai Nortye Ltd. Shareholders Approve Redomiciliation to Singapore - MSN
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Xoma (XOMA) and Adlai Nortye Ltd. Sponsored ADR (ANL) - The Globe and Mail
Why Fonar Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket - Sahm
Adlai Nortye Narrows First-Half 2025 Loss as Oncology Pipeline Advances - The Globe and Mail
Adlai Nortye Ltd ADR (ANL-Q) Stock Price and News - The Globe and Mail
Adlai Nortye licenses cancer drug to ASK Pharm in $230 million deal By Investing.com - Investing.com South Africa
Adlai Nortye shares soar on $230 million licensing deal with ASK Pharm By Investing.com - Investing.com South Africa
Adlai Nortye shares soar on $230 million licensing deal with ASK Pharm - Investing.com India
Adlai Nortye Licenses Pan-RAS Inhibitor AN9025 to ASK Pharm for Greater China - TipRanks
Adlai Nortye licenses cancer drug to ASK Pharm in $230 million deal - Investing.com
Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China - Sahm
Adlai Nortye (NASDAQ:ANL) Trading 1% HigherWhat's Next? - MarketBeat
Adlai Nortye (NASDAQ:ANL) Trading 1% Higher – What’s Next? - Defense World
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Regeneron (REGN) - The Globe and Mail
Adlai Nortye Ltd. Sponsored ADR Cash Flow – LS:A3EEED - TradingView — Track All Markets
Total common shares outstanding of Adlai Nortye Ltd. Sponsored ADR – LS:A3EEED - TradingView — Track All Markets
Analysts Offer Insights on Healthcare Companies: Rigel (RIGL), Terns Pharmaceuticals (TERN) and Pyxis Oncology (PYXS) - The Globe and Mail
Adlai Nortye Ltd Adr Azioni (ANL) Dati Finanziari
Non sono disponibili dati finanziari per Adlai Nortye Ltd Adr (ANL). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.11%
6.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):